SpyGlass Pharma (SGP) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.59
- Estimate
- -$0.55
- Surprise
- -7.8%
- Score today
- 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
SpyGlass Pharma (SGP) reported a wider loss than forecast — diluted EPS of -$0.59 against the -$0.55 estimate (a 7.8% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates SGP Sell at 5.4/10; no pre/post engine snapshot brackets this report.
0 of the last 2 quarters beat the estimate; this quarter's -7.8% surprise compares with a -49.7% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: BIM-IOL System
- Quality below floor (2.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $28.60
- Price target
- $38.28
- Stop
- $26.60
- Upside to target
- +33.8%
- Reward-to-risk
- 2.9:1
Risk check: trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
SGP at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $968.7M
- P/E (fwd)
- -10.7
- 52-week range
- $17.06–$32.44
- Off 52-week high
- 11.8%
- RSI (14)
- 63
- Volume vs avg
- 1.95×
- Score today
- 5.4/10